Drug intelligence / Profile preview

NRT-NMJ_002

Development stage: Preclinical
Lead developer: NEORNAT
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

NRT-NMJ_002 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by NEORNAT for the treatment of lung cancer. The drug is designed to silence a specific, overexpressed DNA replication enzyme that acts as an oncogene. By inhibiting this enzyme, NRT-NMJ_002 aims to suppress the expression of DNA methyltransferases (DNMTs), thereby reversing aberrant DNA methylation patterns and restoring the activity of tumor suppressor genes that are typically silenced in cancer cells. This epigenetic modulation strategy is intended to inhibit tumor growth and progression in lung cancer patients.

Targets

DNMT (DNA methyltransferase)

Beyond the preview

Go deeper on NRT-NMJ_002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRT-NMJ_002.

Explore the full profile